PISCATAWAY, N.J. — GenScript Biotech Corporation reported a surge in financial performance for full year 2025, with revenue reaching $959.5 million, a 61.4% increase year-on-year, according to a company announcement released Monday.
The company, which provides life science research services, biologics development and manufacturing, and industrial biotechnology innovation, attributed the growth to increased license revenue from its LaNova sublicensing agreements, expanded commercial efforts, and rising demand for AI-driven drug development. Gross profit rose to $553.2 million, up 103.3% from 2024, while adjusted net profit reached $230.3 million, a 285% increase.
“2025 was a year of accelerated growth and disciplined execution for GenScript,” said Sherry Shao, Rotating CEO of GenScript Biotech Corporation. “We delivered strong results while continuing to strengthen the integrated capabilities that differentiate GenScript – from gene synthesis and protein engineering to biologics development and industrial biotechnology innovation. Our performance reflects both solid finish-market demand and the benefits of a more connected, globally-scaled operating model.”
Revenue from GenScript Life Science Group (LSG) totaled $522.1 million, a 14.8% year-on-year increase. The company highlighted growth in integrated protein expression services, with revenue up 50%, and a 160% increase in orders flowing from gene synthesis into its integrated protein expression platform. GenScript LSG currently serves over 66,000 active customers globally and has been cited in more than 118,000 publications.
ProBio, the company’s biologics division, experienced particularly strong growth, with revenue reaching $388.7 million, a 309.1% increase year-on-year. ProBio secured 41 antibody and protein drug development projects, 60 cell and gene therapy CDMO projects, and achieved 20 new Investigational New Drug (IND) clearances across cell and gene therapy programs. Fee-for-service revenue for ProBio grew 21% year-on-year, excluding one-time items.
Bestzyme, focused on industrial biotechnology, generated $58.0 million in revenue, a 7.9% increase year-on-year, driven by new enzyme products and AI-enabled research and development. R&D efficiency at Bestzyme improved by 140% due to the implementation of AI-powered workflows.
GenScript reported increased selling and distribution expenses, rising 12.9% to $99.5 million, attributed to expansion of commercial teams and regional recruitment. Administrative expenses increased 12.4% to $128.6 million, reflecting investments in capacity expansion and administrative functions. R&D expenses rose 32.4% to $71.2 million, driven by recruitment of skilled professionals and strategic research initiatives.
The company emphasized its commitment to automation and digitalization, with four major LSG production sites upgraded to automated, AI-driven facilities in 2025. GenScript anticipates that 60% of its global production capacity will be powered by AI-driven automation by the end of 2026.
GenScript also highlighted its progress in Environmental, Social, and Governance (ESG) initiatives, receiving upgrades from MSCI ESG Ratings to AA, inclusion in the FTSE4Good Index Series, an EcoVadis Silver Medal, and inclusion in the S&P Sustainability Yearbook.
Looking ahead to 2026, GenScript expects revenue growth of 15%–18% for LSG, 20%–25% fee-for-service revenue growth for ProBio, and 10%–15% revenue growth for Bestzyme. The company’s focus remains on strengthening cross-platform synergy, broadening global customer reach, and advancing proprietary technologies in biologics and industrial biotechnology.
Recent reports indicate that U.S. Lawmakers have requested a briefing from the FBI regarding GenScript Biotech’s connections to China, according to Reuters. The request, made in early March 2026, seeks further scrutiny of the company’s operations and potential security implications.
